Protein C News and Research

RSS

Researchers find key cellular enzyme that could be effective drug target for urologic cancer cells

Researchers at the SUNY Upstate Medical University have found that a key cellular enzyme, c-Abl, could be an effective drug target in cancer cells for urologic cancers, such as prostate and kidney.

11 Sep 2015

Researchers now have a way to study special proteins linked to different diseases, cancer

Researchers from Northwestern University and Yale University have developed a user-friendly technology to help scientists understand how proteins work and fix them when they are broken. Such knowledge could pave the way for new drugs for a myriad of diseases, including cancer.

11 Sep 2015

NYU's Jin Kim Montclare develops dual-delivery system to potentially treat multi-drug resistant cancer cells

The National Science Foundation recently funded research aimed at developing an engineered protein-lipid system that simultaneously delivers genes and drugs for the potential treatment of multi-drug resistant cancer cells. The dual-delivery system could also apply to diabetes and other conditions requiring a variety of therapeutic approaches.

11 Sep 2015

Research: Cancer preventative surgery may not be necessary in the future

Surgery to remove the breasts of women at increased risk of developing breast cancer may not be necessary in the future, according to research published in EBioMedicine. Two new studies looking at the effect the menstrual cycle has on the development of breast and ovarian cancer reveal alternative prevention strategies that may render surgery unnecessary.

11 Sep 2015

Chronic alcohol consumption disrupts liver molecular circadian clock, leads to alcoholic liver disease

The activity of an organ in the body changes through the day and is governed by its internal clock, also known as a circadian clock. Staying on a circadian schedule is important for health, and disruptions lead to disease.

11 Sep 2015

Molecular Health enters into license agreement to supply SafetyMAP software to FDA

Molecular Health has entered into a commercial license to provide the FDA with use of its SafetyMAP software - formally known as Molecular Analysis of Side Effect information (MASE), to provide a comprehensive and dynamic analytical solution for the detection and molecular analysis of drug-induced adverse events for all marketed drugs and for predicting safety issues of new drug candidates.

11 Sep 2015

Researchers discover new strategy for attacking cancer cells

University of Virginia School of Medicine researchers have discovered a new strategy for attacking cancer cells that could fundamentally alter the way doctors treat and prevent the deadly disease.

11 Sep 2015

EMBL researchers use mass spectrometry data to analyze effects of cancer drugs

Researchers at EMBL's European Bioinformatics Institute (EMBL-EBI) have developed a new method for studying the targets and effects of cancer drugs using data from discovery mass spectrometry (MS) experiments.

11 Sep 2015

UVA researchers identify new strategy for attacking cancer cells

University of Virginia School of Medicine researchers have discovered a new strategy for attacking cancer cells that could fundamentally alter the way doctors treat and prevent the deadly disease. By more selectively targeting cancer cells, this method offers a strategy to reduce the length of and physical toll associated with current treatments.

10 Sep 2015

Signs of Alzheimer’s found in growth hormone patients

People may be able to contract Alzheimer’s disease during certain medical procedures in the same way that Creutzfeldt-Jakob disease (CJD) is transmitted, suggest researchers from University College London.

10 Sep 2015

First patient dosed in long term-safety extension study of Resolaris for adult patients with FSHD

aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced that the first patient has been dosed in a newly initiated long term-safety extension study of Resolaris for adult patients with facioscapulohumeral muscular dystrophy (FSHD), a rare and severe genetic myopathy for which there are currently no approved treatments.

10 Sep 2015

Rice lab invents technique to characterize nanoscale spaces in porous materials

Rice University scientists led a project to "see" and measure the space in porous materials, even if that space is too small or fragile for traditional microscopes.

10 Sep 2015

CureVac, IAVI team up to advance development, testing of AIDS vaccines

The non-profit International AIDS Vaccine Initiative (IAVI) and biopharmaceutical company CureVac are partnering to accelerate the development of AIDS vaccines, utilizing novel immunogens developed by IAVI and partners, delivered via CureVac's novel messenger RNA (mRNA) technology.

10 Sep 2015

CureVac announces official launch of U.S. operations in Cambridge, MA

CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announced the official launch of its U.S. operations in Cambridge, MA, as the company advances the development of its proprietary mRNA platform technology and multiple, clinical-stage mRNA therapeutics and vaccines.

10 Sep 2015

A new approach to prevent breast and ovarian cancer

Surgery to remove the breasts of women at increased risk of developing breast cancer may not be necessary in the future, according to research published in EBioMedicine.

10 Sep 2015

Researchers use nanopore technology for early detection of colorectal and lung cancers

Using tiny "nanopore" scanners that can detect individual DNA molecules, Professor Amit Meller and colleagues are on the hunt for biological markers in cancer cells that may help clinicians diagnose colorectal and lung cancers at their earliest stages.

10 Sep 2015

Innovative vaccine therapy shows promise against glioblastoma brain tumors

An innovative vaccine therapy developed at Roswell Park Cancer Institute is being tested in a multisite clinical trial involving 50 patients with newly diagnosed glioblastoma brain tumors. The phase II study, now accruing patients at both Roswell Park and the Cleveland Clinic, will assess the effectiveness of the SurVaxM vaccine in combination with standard chemotherapy as treatment for this often-fatal cancer.

10 Sep 2015

Worldwide Protein Data Bank symposium focuses on multi-scale structural biology

The symposium titled with "Integrative Structural Biology with Hybrid Methods" is held focusing on the multi-scale structural biology, which aims to analyze structures of protein molecules and their assemblies, cellular machines, organelle, and even living cells and organisms by the hybrid methods, integrating many different technologies, such as chemical cross-links, MS spectrometry, FRET, Super-resolution microscopy, X-ray diffraction, NMR, and Computer modeling, in addition to Cryo-electron microscopy that has been attracting much attention these days.

10 Sep 2015

Research opens up potential new pathways to vaccine development against HA-MRSA

New research led by NYU Langone Medical Center has uncovered why a particular strain of Staphylococcus aureus -- known as HA-MRSA -- becomes more deadly than other variations. These new findings open up possible new pathways to vaccine development against this bacterium, which the Centers for Disease Control and Preventions says accounts for over 10,000 deaths annually, mostly among hospital patients.

10 Sep 2015

HUCBC-derived monocytes diminishes Aβ pathology, improves cognition in AD modeled mice

Alzheimer's disease (AD), which affects an estimated 26 million people worldwide, is the fourth leading cause of death among the elderly and the leading cause of dementia. Predictions are that the number of AD cases will quadruple by 2050.

9 Sep 2015

Protein C News and Research

Researchers find key cellular enzyme that could be effective drug target for urologic cancer cells

Researchers now have a way to study special proteins linked to different diseases, cancer

NYU's Jin Kim Montclare develops dual-delivery system to potentially treat multi-drug resistant cancer cells

Research: Cancer preventative surgery may not be necessary in the future

Chronic alcohol consumption disrupts liver molecular circadian clock, leads to alcoholic liver disease

Molecular Health enters into license agreement to supply SafetyMAP software to FDA

Researchers discover new strategy for attacking cancer cells

EMBL researchers use mass spectrometry data to analyze effects of cancer drugs

UVA researchers identify new strategy for attacking cancer cells

Signs of Alzheimer’s found in growth hormone patients

First patient dosed in long term-safety extension study of Resolaris for adult patients with FSHD

Rice lab invents technique to characterize nanoscale spaces in porous materials

CureVac, IAVI team up to advance development, testing of AIDS vaccines

CureVac announces official launch of U.S. operations in Cambridge, MA

A new approach to prevent breast and ovarian cancer

Researchers use nanopore technology for early detection of colorectal and lung cancers

Innovative vaccine therapy shows promise against glioblastoma brain tumors

Worldwide Protein Data Bank symposium focuses on multi-scale structural biology

Research opens up potential new pathways to vaccine development against HA-MRSA

HUCBC-derived monocytes diminishes Aβ pathology, improves cognition in AD modeled mice

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News